Thromb Haemost 1969; 21(01): 594-603
DOI: 10.1055/s-0038-1653572
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

Comparative Study of Proactivators of the Fibrinolysin System in Three Mammalian Species

Y Takada
1  Springville Laboratories, Roswell Park Memorial Institute and the State University of New York at Buffalo, Buffalo, New York, 14203
,
A Takada
1  Springville Laboratories, Roswell Park Memorial Institute and the State University of New York at Buffalo, Buffalo, New York, 14203
,
J. L Ambrus
1  Springville Laboratories, Roswell Park Memorial Institute and the State University of New York at Buffalo, Buffalo, New York, 14203
› Author Affiliations
This study was supported by grant 67-900 from the American Heart Association, a grant from the Erie County Heart Association, New York State Heart Assembly, Inc., and grants HE-11591, HE-04418, and CA-05136 from the National Institutes of Health, U.S. Public Health Service. Drs. Y. Takada and A. Takada held fellowships in hematology from the United Health Foundation of Western New York.
Further Information

Publication History

Publication Date:
10 June 2018 (online)

Summary

Sephadex gel filtration of human plasma gave results suggesting the presence of two proactivators of plasminogen, termed proactivators A and B.

Activity resembling that of proactivator A was found in rabbit plasma, but not in guinea pig plasma.

Plasminogen activators produced by the interaction of proactivator A of human plasma with streptokinase had no caseinolytic or TAMe esterolytic effect.

Proactivator A can be separated in a form apparently free from plasminogen, as shown by the heated fibrin plate test and by immunological analysis. On the other hand, proactivator B concentrates prepared so far are contamined with plasminogen.

Human proactivators appear to be far more susceptible to streptokinase than are rabbit proactivators.

Inhibitors of the fibrinolysin system were observed in the plasmas of all 3 species. These inhibitors are not present in the euglobulin fraction of plasma. Sephadex fractionation of euglobulin fractions results in proactivator preparations that do not contain inhibitors.